SHARE - Symbicort and Health Economics in a Real Life Evaluation
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare health-related costs and asthma control in ordinary
clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as
needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and
Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately
controlled on inhaled glucocorticosteroids alone.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate Terbutaline